Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.
about
The role of RANK-ligand inhibition in cancer: the story of denosumabRe-HEDP : pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dosePatient experience in the treatment of metastatic castration-resistant prostate cancer: state of the scienceComparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trialsThe role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancerRadionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerBone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to boneRadium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis.Prostate cancer: 11. Alternative approaches and the future of treatmentPhase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancerProstate cancer: 10. Palliative care.NCCN Task Force Report: Bone Health in Cancer Care.External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG.Radium-223 for the treatment of castration-resistant prostate cancer.Recent advances in the therapy of castration-resistant prostate cancer: the price of progress.Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer.Castration-resistant prostate cancer: mechanisms, targets, and treatment.The evolving biology and treatment of prostate cancer.Radionuclide Therapy of Bone Metastases.Improving external beam radiotherapy by combination with internal irradiationLess pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancerBone-targeted agents: preventing skeletal complications in prostate cancer.Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Multimodality therapy: bone-targeted radioisotope therapy of prostate cancerManagement of docetaxel failures in metastatic castrate-resistant prostate cancer.Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid.Bone pain and radionuclide therapy.Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.Chemotherapy for hormone-resistant prostate cancer: Where are we today?Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride.Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII).Role of Radionuclide Therapy as Adjuvant to Palliative External Beam Radiotherapy for Painful Multiple Skeletal Metastasis.EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer.
P2860
Q24633284-7B82AF5C-89FD-4871-AA6F-19DEEECE2963Q24796082-D7186E93-5C2B-45B9-A2ED-C2B422627B5BQ26772883-BCA82A0A-765A-45CF-8828-FB063E116DEEQ26785658-E6E02805-8E0D-40B9-B8BA-C80FD9525D58Q26823733-386A44C0-11D0-4D85-98BF-EBD42279560AQ28079918-A60EEC9D-3120-469E-8B54-D310C68F43DEQ30852837-882FEA7C-EBC2-4342-A0F0-0310831D54A9Q33343008-A7BA38A4-274C-4A3F-BAF8-542C45587775Q33405335-2F6203FA-B2A7-48CA-922B-754A24E4ABD5Q33408024-959C8310-E444-4F08-95E4-4D4AC2513D27Q33419135-49D2F874-6AC1-4143-9CBB-23FA0D76489FQ33542346-6BE713CA-B713-4522-A794-AF508860001DQ33789188-81DFCAF8-4F3E-4D3F-A29E-22CBCBA6AF31Q34023510-35068D47-594B-4FE2-9727-3E8D233DC7D3Q34030661-8FEA3F8A-2435-450E-8A2C-870C73E3B406Q34617936-A62D180C-45A1-4CD7-95FF-2E2175D10764Q35171949-030EF10E-2E85-424E-A329-CB89695ED007Q35653986-F5129C8D-446C-422F-8FFB-011924E673FCQ35660931-F029932A-0DAA-484E-8880-3A20C95C0724Q35743202-6166573E-6305-4EDC-8568-A2BE6F21000BQ35864027-90FE8D45-83C1-4315-B09B-D87EA4F88EF6Q35951473-BDA7F797-EBCA-423E-B955-7D47185E79B0Q36036136-FE955841-9B1F-4473-B80E-6AFF6367DECCQ36235732-12210CA1-3BA8-45A8-A9B7-419C3D06D547Q36622555-D4FAB9F9-4929-44BF-A7FD-1E7566C19739Q37039594-4E42988D-11B4-4CF4-91DE-CF2014009530Q37166534-F506A237-A368-41FF-9E61-FCC47B711EF1Q37187646-ACA451E2-C886-4A9B-B4E6-08EA7EBA74C0Q37193613-51DA8FD3-C4E2-4CF2-87FC-F02E5D88F10CQ37354571-EB3B02B3-AD6D-4D27-A81F-CE69FE419B15Q38004275-9109427B-311E-4388-9834-AF00EA008F6DQ39187541-46E540ED-91B1-4E7E-8113-67EFD10693CDQ40396470-77353AD4-EB5E-4263-BC94-39E191A91526Q42082392-9A6B15A9-DEE4-4D62-8C6F-3E3768DAAE40Q42119686-0F1946E9-7860-42B4-8DD4-063C83596EDFQ42433816-A586B7C8-1523-42E7-AD87-CC71AB65638BQ46718088-4C90ABBF-61D9-41E5-8988-1B240D04CD9CQ47142819-ADBE9374-7979-4576-A1F4-A6A3BE7CF4AEQ49908522-93B02E7F-A52D-46EF-9CC3-83125D0AB1C7Q55158890-AAB7D9A5-FF5B-4DFF-9022-0309AB7EBEB9
P2860
Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Results of a randomized phase- ...... nt metastatic prostate cancer.
@en
Results of a randomized phase- ...... nt metastatic prostate cancer.
@nl
type
label
Results of a randomized phase- ...... nt metastatic prostate cancer.
@en
Results of a randomized phase- ...... nt metastatic prostate cancer.
@nl
prefLabel
Results of a randomized phase- ...... nt metastatic prostate cancer.
@en
Results of a randomized phase- ...... nt metastatic prostate cancer.
@nl
P2093
P1476
Results of a randomized phase- ...... ant metastatic prostate cancer
@en
P2093
A J McEwan
A T Porter
D G McGowan
G M Thomas
J R Sathyanarayana
L E Erlich
V N Yakemchuk
P304
P356
10.1016/0360-3016(93)90309-J
P407
P577
1993-04-01T00:00:00Z